JAVIER
DE JUAN BAGUDA
PROFESOR
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (20)
2024
-
Baroreflex activation therapy in patients with heart failure and reduced ejection fraction
Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 342-344
-
Design and baseline characteristics of SALT-HF trial: hypertonic saline therapy in ambulatory heart failure
ESC Heart Failure
-
Repetitive ambulatory levosimendan as a bridge to heart transplantation
Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 290-301
-
Review of the allocation criteria for heart transplant in Spain in 2023. SEC-Heart Failure Association/ONT/SECCE consensus document
Revista Espanola de Cardiologia, Vol. 77, Núm. 1, pp. 69-78
2023
-
Conduction system pacing and atrioventricular node ablation in heart failure: The PACE-FIB study design
ESC Heart Failure, Vol. 10, Núm. 6, pp. 3700-3709
-
De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians
Journal of Clinical Medicine, Vol. 12, Núm. 23
-
Do Women Physicians Accept and Follow Heart Failure Guidelines More Than Men?
Current Heart Failure Reports, Vol. 20, Núm. 3, pp. 151-156
-
Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction
Clinical Research in Cardiology
-
Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry
ESC Heart Failure, Vol. 10, Núm. 2, pp. 1193-1204
-
Opinion on the 2021 ESC guidelines on heart failure: a cross-sectional survey of 387 doctors
REC: CardioClinics, Vol. 58, Núm. 1, pp. 7-15
-
Vericiguat in the current management of the patients with heart failure
REC: CardioClinics
2022
-
Impact of blood pressure on management and prognosis of patients treated with sacubitril/valsartan
REC: CardioClinics, Vol. 57, Núm. 2, pp. 116-122
-
Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics
Journal of Clinical Medicine, Vol. 11, Núm. 5
2021
-
Initiation and titration of sacubitril/valsartan in different types of centers
REC: CardioClinics, Vol. 56, Núm. 2, pp. 92-97
-
Physiopathology, diagnosis, and management of hypomagnesemia in heart failure patients
REC: CardioClinics
2020
-
Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort
Revista Espanola de Geriatria y Gerontologia, Vol. 55, Núm. 2, pp. 65-69
2019
-
Sacubitril/Valsartan in Daily Clinical Practice: Data from a Prospective Registry
Journal of Cardiovascular Pharmacology, Vol. 73, Núm. 2, pp. 118-124
-
Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort
ESC Heart Failure, Vol. 6, Núm. 6, pp. 1161-1166
-
Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan
Cardiology (Switzerland), Vol. 142, Núm. 2, pp. 73-78
2018
-
Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial
Journal of cardiovascular pharmacology, Vol. 72, Núm. 2, pp. 112-116